Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice - Maegawa, H; Tobe, K; Tabuchi, H (Expert Opin Pharmacother, 2016)
et al.